Form 4: CRISPR Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, sold 10,400 shares of common stock on September 22, 2026 for $60.24 per share.
Summary
- Option exercise/conversion: acquired 10,400 Common Shares at $13.62 ($141,648) on September 22, 2026; holds 105,184 after (Direct).
- Open-market sale: disposed of 10,400 Common Shares at $60.24 ($626,460) on September 22, 2026; holds 94,784 after (Direct).
- Option exercise/conversion: disposed of 10,400 Stock Option (Right to Buy) on September 22, 2026; holds 83,232 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $626,460 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
James R. Kasinger — Officer (General Counsel and Secretary)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-22 | Option exercise/conversion | Common Shares | 10,400 | $14 | $141.6K | 105,184 |
| 2026-09-22 | Open-market sale | Common Shares | 10,400 | $60 | $626.5K | 94,784 |
| 2026-09-22 | Option exercise/conversion | Stock Option (Right to Buy) | 10,400 | — | — | 83,232 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-22 | Option exercise/conversion (10,400 shares) |
| 2026-09-22 | Open-market sale (10,400 shares) |
| 2026-09-22 | Option exercise/conversion (10,400 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, James R. Kasinger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.